Log in to save to my catalogue

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 201...

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 201...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2708223192

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study

About this item

Full title

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study

Publisher

London: Elsevier Ltd

Journal title

The lancet oncology, 2022-09, Vol.23 (9), p.1201-1210

Language

English

Formats

Publication information

Publisher

London: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundPrimary chemotherapy in breast cancer poses a dilemma with regard to adjuvant locoregional radiotherapy, as guidelines for locoregional radiotherapy were originally based on pathology results of primary surgery. We aimed to evaluate the oncological safety of de-escalated locoregional radiotherapy in patients with cT1–2N1 breast can...

Alternative Titles

Full title

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2708223192

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2708223192

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(22)00482-X

How to access this item